Business
ETST Announces the Execution of a Binding LOI to Acquire 100% of the Assets of a Canadian Biotech Company Specializing in Medical Devices, Testing and Vaccines and Forms New Wholly Owned Subsidiary, Earth Science Pharmaceutical, Inc.
ETST Announces the Execution of a Binding LOI to Acquire 100% of the Assets of a Canadian Biotech Company Specializing in Medical Devices, Testing and Vaccines and Forms New Wholly Owned Subsidiary, Earth Science Pharmaceutical, Inc..
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Boca Raton, June 20, 2016 (GLOBE NEWSWIRE) --  Earth Science Tech, Inc. (OTCQB: ETST) (the “Company”), a publicly traded biotechnology company that develops, produces and sells nutraceutical products among which is its leading High Grade Hemp CBD (Cannabidiol) Oil which most recently launched a Clinical Study with 9/11 First Responders, announces ETST has executed a binding letter of intent to acquire all the assets of BEO ITS, Inc., a company engaged in the development of medical devices, tests and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Based on the final definitive asset purchase agreement, ETST has formed a new wholly owned subsidiary, Earth Science Pharmaceutical, Inc., domiciled in the state of Florida. In addition, Dr. Michel Aubé, the CEO and principal owner of BEO ITS, Inc. will be elected effective today as the CEO of Earth Science Pharmaceutical, Inc., a wholly owned subsidiary of ETST.\n Nickolas Tabraue, COO of Earth Science Tech, Inc. stated, “This letter of intent for the asset purchase acquisition of BEO ITS, Inc. will help diversify the company's business into new markets including the medical, medical device and pharmaceutical industry. I am excited to be working with Dr. Michele Aubé, a renowned scientist, who is committed to help grow Earth Science Tech, Inc. in the medical and pharmaceutical industry.\" Dr. Michel Aubé has wide-ranging expertise in the life sciences. As a microbiologist he furthered his graduate studies at Laval University, earning a Master’s degree in Cell Biology and Molecular Physiology as well as a PhD in Physiology-Endocrinology. In addition, he created and taught three postdoctoral courses in Immunology. His scientific research in Sexually Transmitted Infections (STIs), Cancer and Stem Cell biology has been published in several prestigious medical journals. Dr. Aubé has received a number of Awards for Excellence from the Network for environmental health research and childhood diseases. Dr. Michel Aubé commented, “I am honored to be named the new CEO of Earth Science Pharmaceutical, Inc., the wholly owned subsidiary of Earth Science Tech, Inc., and I personally look forward to helping the company become a world leader in the development of low cost, non-invasive diagnostic tools, medical d...